{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1192"}]}],"title":"EP2006 - Group 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"}]}],"title":"EP2006 - Group 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"212"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 7: To identify different latent clusters of end-stage cancer patients receiving chemotherapy and being treated with EP2006 for the treatment or primary or secondary prophylaxis of FN using statistical data-mining techniques to profile patients based on medical history, concomitant comorbid conditions, and current clinical status.\n\nA two-group solution converged and the groups differentiated on key baseline variables. However, the group sizes were too unevenly distributed for further analysis with the \"high risk group\" comprised of only 3.0% of the evaluable sample.\n\nANC=Absolute Neutrophil Count; CIN=Chemotherapy-Induced Neutropenia; FN=Febrile Neutropenia","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006 - Group 1"}],"paramType":"NUMBER","populationDescription":"The evaluable sample consists of all patients who received at least one dose of study medication, had no major protocol violation and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data (i.e., ANC or completed CIN/FN data).","reportingStatus":"POSTED","timeFrame":"Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"Cohort Identification","type":"SECONDARY","unitOfMeasure":"participants"}